entertainment -WSS

entertainment

author：focus 2025-10-02 00:18:58 - browse：17

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： 'A game

entertainment

WSS

Young boy dies in trial for Pfizer Duchenne gene therapy

Scientists uncover potential path to treating deadly childhood tumor

'A game

'A game

Florida Supreme Court upholds state's abortion ban

Bird flu reported in person exposed to presumably infected cattle

entertainment

entertainment

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

What happened to the House vote on health price transparency?

Dobbs anniversary: the lost opportunity of abortion as health care

Midwives could help bridge maternal health disparities in the U.S.

Novavax promises a turnaround & Lilly roils the obesity market

Midwives could help bridge maternal health disparities in the U.S.

Walensky prepares to leave CDC — and Congress — behind

Grad students accuse University of California of wage theft

Trump demands the U.S. pay no more for drugs than other countries … again

Transgender sports debate: Physicians say bans are health issue

hotspot

Mass General Brigham physicians react to latest merger step

Scientific mystery highlights the blind spots in genomics databases

FDA panel to weigh safety of artificial wombs for preterm births

Information blocking fines are now fair game in health care

Oral obesity drug from Viking Therapeutics hits key early target

David Liu startup to focus on CRISPR delivery

focus

entertainment

entertainment

hotspot